Romidepsin and azacitidine in patients with R/R T-cell lymphoma

0 Views
administrator
administrator
07/14/23

Matko Kalac, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, shares some updates from a retrospective analysis investigating the use of romidepsin and azacitidine in patients with relapsed/refractory (R/R) T-cell lymphoma. Dr Kalac first comments on the need to improve treatment options for patients with this disease and then discusses the safety and tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next